We aim to develop innovative disease-modifying therapeutics to preserve and improve patients’ vision. The strength of our ophthalmology pipeline derives from our strong clinical development capability and close collaboration with industry and academic partners coupled with our deep scientific knowledge of diseases affecting the eye.
With a diverse portfolio of drugs and drug candidates at different stages of development, we are focused on bringing patients safe and effective, best-in-class therapeutics for a spectrum of ophthalmic diseases in both the front and the back of the eye. The ophthalmic disease states we are targeting all are underserved clinically, with significant unmet medical needs in Greater China and other Asian countries.
| Program | Lead Indication | AffaMed Territory | Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
AM007DEXTENZA Detail |
Post surgical pain/infl, AC | Greater China, Korea, SEA |
  |
|||||||||
|
AM008OTX-TIC Detail |
Glaucoma | Greater China, Korea, SEA |
|
|||||||||
|
IOLs Detail |
Cataract | Greater China |
|
|||||||||
|
AM305AG-73305 Detail |
DME, nAMD, RVO | Greater China, South Korea & SEA |
|
|||||||||
|
AM011Luminate Detail |
Dry AMD | Greater China |
|
|||||||||
|
AM712ASKG712 Detail |
nAMD, DME | Global (excl. Asia & Japan) |
|
|||||||||
|
AM002SB11/Ranibizumab Detail |
wAMD, DME, RVO | Mainland China, Singapore |
|
|||||||||
|
AM003SB15/Aflibercept Detail |
wAMD, DME | Mainland China, Singapore |
|
|||||||||
|
AM007DEXTENZA
Read More |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Lead Indication
Post surgical pain/infl, AC
|
|||||||||
|
AffaMed Territory
Greater China, Korea, SEA
|
|||||||||
| Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|
|
|||||||||
|
AM008OTX-TIC
Read More |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Lead Indication
Glaucoma
|
|||||||||
|
AffaMed Territory
Greater China, Korea, SEA
|
|||||||||
| Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|
|
|||||||||
|
IOLs
Read More |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Lead Indication
Cataract
|
|||||||||
|
AffaMed Territory
Greater China
|
|||||||||
| Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|
|
|||||||||
|
AM305AG-73305
Read More |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Lead Indication
DME, nAMD, RVO
|
|||||||||
|
AffaMed Territory
Greater China, South Korea & SEA
|
|||||||||
| Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|
|
|||||||||
|
AM011Luminate
Read More |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Lead Indication
Dry AMD
|
|||||||||
|
AffaMed Territory
Greater China
|
|||||||||
| Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|
|
|||||||||
|
AM712ASKG712
Read More |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Lead Indication
nAMD, DME
|
|||||||||
|
AffaMed Territory
Global (excl. Asia & Japan)
|
|||||||||
| Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|
|
|||||||||
|
AM002SB11/Ranibizumab
Read More |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Lead Indication
wAMD, DME, RVO
|
|||||||||
|
AffaMed Territory
Mainland China, Singapore
|
|||||||||
| Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|
|
|||||||||
|
AM003SB15/Aflibercept
Read More |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Lead Indication
wAMD, DME
|
|||||||||
|
AffaMed Territory
Mainland China, Singapore
|
|||||||||
| Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|
|
|||||||||
We focus on neurology & psychiatry therapeutic areas with high unmet medical needs and great market potential.
Our partnerships with Chinese and global biopharmaceutical companies enhance our portfolio of innovative drug candidates in neurological and psychiatric diseases like Parkinson’s Disease (AD), social anxiety disorder (SAD), myasthenia gravis and ophthalmoneuromyelitis.
| Program | Lead Indication | AffaMed Territory | Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
AM004SB12/Eculizumab Detail |
PNH, aHUS, gMG, NMOSD | Mainland China, Singapore |
|
|||||||||
|
AM005PH94B Detail |
Social anxiety disorder | Greater China, Korea, SEA |
|
|||||||||
|
AM006KDT-3594 Detail |
Parkinson’s disease | Greater China, SEA |
|
|||||||||
|
AMD201 Detail |
PSCI | Global |
|
|||||||||
|
AMD202 Detail |
ADHD | Global (excl. China) |
|
|||||||||
|
AM004SB12/Eculizumab
Read More |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Lead Indication
PNH, aHUS, gMG, NMOSD
|
|||||||||
|
AffaMed Territory
Mainland China, Singapore
|
|||||||||
| Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|
|
|||||||||
|
AM005PH94B
Read More |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Lead Indication
Social anxiety disorder
|
|||||||||
|
AffaMed Territory
Greater China, Korea, SEA
|
|||||||||
| Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|
|
|||||||||
|
AM006KDT-3594
Read More |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Lead Indication
Parkinson’s disease
|
|||||||||
|
AffaMed Territory
Greater China, SEA
|
|||||||||
| Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|
|
|||||||||
|
AMD201
Read More |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Lead Indication
PSCI
|
|||||||||
|
AffaMed Territory
Global
|
|||||||||
| Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|
|
|||||||||
|
AMD202
Read More |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Lead Indication
ADHD
|
|||||||||
|
AffaMed Territory
Global (excl. China)
|
|||||||||
| Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|
|
|||||||||
